梅花生物(600873.SH):2025年員工持股計劃購買完成
格隆匯8月1日丨梅花生物(600873.SH)公佈,截至2025年8月1日收盤,公司2025年員工持股計劃專戶通過二級市場以集中競價交易方式累計買入公司股份21,042,422股,佔公司目前股本總數(2,852,788,750股)的0.74%,成交均價約爲10.70元/股,成交金額爲人民幣225,143,665.20元(不含交易費用)。根據公司2025年第一次臨時股東大會批準的方案,公司2025年員工持股計劃已完成購買計劃,購買的公司股票將按照規定予以鎖定,鎖定期自本公告披露之日起滿12個月、24個月後分兩期解鎖,最長鎖定期爲24個月,每期解鎖的標的股票比例分別爲50%、50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.